

MEDICAL SCIENCES

Correction for “A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model,” by Brian C. Capell, Michelle Olive, Michael R. Erdos, Kan Cao, Dina A. Faddah, Urraca L. Tavarez, Karen N. Conneely, Xuan Qu, Hong San, Santhi K. Ganesh, Xiaoyan Chen, Hedwig Avallone, Frank D. Kolodgie, Renu Virmani, Elizabeth G. Nabel, and Francis S. Collins, which appeared in issue 41, October 14, 2008, of *Proc Natl Acad Sci USA* (105:15902–15907; first published October 6, 2008; 10.1073/pnas.0807840105).

The authors note that the description of the dosing of farnesyltransferase inhibitor (FTI) tipifarnib was incorrect. The article states that the drug was delivered in mg/kg of mouse total body weight. However, the actual study design was based on the concentration of the FTI drug in the diet (mg of FTI mixed in 1 kg of transgenic mouse dough). This dosing protocol was based on prior pharmacokinetic data, and the biomarker data included in the paper shows the desired drug effects were achieved. This error does not affect the conclusions of the article.

www.pnas.org/cgi/doi/10.1073/pnas.0907672106